Biogen Inc. (SNSE:BIIB)

Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of CLP 21.60 trillion. The enterprise value is 24.08 trillion.

Market Cap	21.60T
Enterprise Value	24.08T

Important Dates

The last earnings date was Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.70M
Shares Outstanding	n/a
Shares Change (YoY)	+0.36%
Shares Change (QoQ)	+0.27%
Owned by Insiders (%)	0.17%
Owned by Institutions (%)	90.14%
Float	146.31M

Valuation Ratios

The trailing PE ratio is 13.96 and the forward PE ratio is 11.79.

PE Ratio	13.96
Forward PE	11.79
PS Ratio	2.23
PB Ratio	1.23
P/TBV Ratio	9.42
P/FCF Ratio	9.75
P/OCF Ratio	9.15
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.22, with an EV/FCF ratio of 10.87.

EV / Earnings	15.57
EV / Sales	2.53
EV / EBITDA	7.22
EV / EBIT	9.62
EV / FCF	10.87

Financial Position

The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.36.

Current Ratio	2.72
Quick Ratio	1.77
Debt / Equity	0.36
Debt / EBITDA	1.87
Debt / FCF	2.86
Interest Coverage	10.18

Financial Efficiency

Return on equity (ROE) is 9.31% and return on invested capital (ROIC) is 6.92%.

Return on Equity (ROE)	9.31%
Return on Assets (ROA)	5.75%
Return on Invested Capital (ROIC)	6.92%
Return on Capital Employed (ROCE)	10.21%
Revenue Per Employee	1.27B
Profits Per Employee	203.39M
Employee Count	7,605
Asset Turnover	0.35
Inventory Turnover	1.01

Taxes

In the past 12 months, Biogen has paid 284.16 billion in taxes.

Income Tax	284.16B
Effective Tax Rate	15.52%

Stock Price Statistics

The stock price has decreased by -46.84% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-46.84%
50-Day Moving Average	130.24
200-Day Moving Average	184.18
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.16

Income Statement

In the last 12 months, Biogen had revenue of CLP 9.68 trillion and earned 1.55 trillion in profits. Earnings per share was 10,553.51.

Revenue	9.68T
Gross Profit	7.41T
Operating Income	2.54T
Pretax Income	1.83T
Net Income	1.55T
EBITDA	3.28T
EBIT	2.54T
Earnings Per Share (EPS)	10,553.51

Balance Sheet

The company has 3.81 trillion in cash and 6.34 trillion in debt, giving a net cash position of -2,528.75 billion.

Cash & Cash Equivalents	3.81T
Total Debt	6.34T
Net Cash	-2,528.75B
Net Cash Per Share	n/a
Equity (Book Value)	17.51T
Book Value Per Share	119,349.11
Working Capital	5.43T

Cash Flow

In the last 12 months, operating cash flow was 2.36 trillion and capital expenditures -143.47 billion, giving a free cash flow of 2.22 trillion.

Operating Cash Flow	2.36T
Capital Expenditures	-143.47B
Free Cash Flow	2.22T
FCF Per Share	n/a

Margins

Gross margin is 76.56%, with operating and profit margins of 26.28% and 15.98%.

Gross Margin	76.56%
Operating Margin	26.28%
Pretax Margin	18.92%
Profit Margin	15.98%
EBITDA Margin	33.87%
EBIT Margin	26.28%
FCF Margin	22.89%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.36%
Shareholder Yield	-0.36%
Earnings Yield	7.16%
FCF Yield	10.26%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 3 and a Piotroski F-Score of 6.

Altman Z-Score	3
Piotroski F-Score	6